Effects of different progestogens on human breast tumor cell growth

References

• Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–33
   PubMed Web of Science ®Google Scholar
• Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. Lancet 2003;362:419–27
   PubMed Web of Science ®Google Scholar
• The Women's Health Initiative Steering Committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. JAMA 2004;291:1701–12
   PubMed Web of Science ®Google Scholar
• Peck JD, Hulka BS, Poole C, Savitz DA, Baird D, Richardson BE. Steroid hormone levels during pregnancy and incidence of maternal breast cancer. Cancer Epidemiol Biomarkers Prev 2002;11:361–8
   PubMed Web of Science ®Google Scholar
• Campagnoli C, Abbà C, Ambroggio S, Peris C. Pregnancy, progesterone and progestins in relation to breast cancer risk. J Steroid Biochem Mol Biol 2005;97:441–50
   PubMed Web of Science ®Google Scholar
• Pasqualini JR. The fetus, pregnancy and breast cancer. Breast Cancer: Prognosis, Treatment, and Prevention. In Pasqualini JR, ed, New York: Marcel Dekker Inc; 200219–71
   Google Scholar
• Speroff L, Glass RH, Kase MG. The Endocrinology of Pregnancy in Clinical Gynecologic Endocrinology and Infertility. Philadelphia: Lippincott Williams & Wilkins; 1999275–335
   Google Scholar
• Micheli A, Muti P, Secreto G, et al. Endogenous sex hormones and subsequent breast cancer in pre-menopausal women. Int J Cancer 2004;112:312–18
   PubMed Web of Science ®Google Scholar
• Bernstein L, Yuan JM, Ross RK, et al. Serum hormone levels in pre-menopausal Chinese women in Shanghai and white women in Los Angeles: results from two breast cancer case-control studies. Cancer Causes Control 1990;1:51–8
   PubMed Web of Science ®Google Scholar
• Drafta D, Schindler AE, Milcu SM, et al. Plasma hormones in pre- and post-menopausal breast cancer. J Steroid Biochem 1980;13:793–802
   PubMedGoogle Scholar
• Malarkey WB, Schroeder LL, Stevens VC, James AG, Lanese RR. Twenty-four-hour preoperative endocrine profiles in women with benign and malignant breast disease. Cancer Res 1977;37:4655–9
   PubMed Web of Science ®Google Scholar
• Meyer F, Brown JB, Morrison AS, MacMahon B. Endogenous sex hormones, prolactin, and breast cancer in premenopausal women. J Natl Cancer Inst 1986;77:613–16
   PubMed Web of Science ®Google Scholar
• Secreto G, Toniolo P, Berrino F, et al. Increased androgenic activity and breast cancer risk in premenopausal women. Cancer Res 1984;44:5902–5
   PubMed Web of Science ®Google Scholar
• Schindler AE, Campagnoli C, Druckmann R, et al. Classification and pharmacology of progestins. Maturitas 2003;46(Suppl 1):s7–16
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ. All progestins are not created equal. Steroid 2003;68:879–90
   PubMed Web of Science ®Google Scholar
• Clarke CL, Sutherland RL. Progestin regulation of cellular proliferation. Endocr Rev 1990;11:266–301
   PubMed Web of Science ®Google Scholar
• Formby B, Wiley TS. Bcl-2, surviving and variant cd44 v7-v10 are downregulated and P53 is upregulated in breast cancer cells by progesterone: inhibition of cell growth and induction of apoptosis. Mol Cell Biochem 1999;202:53–61
   PubMed Web of Science ®Google Scholar
• Gompel A, Somai S, Chaouat M, et al. Hormone regulation of apoptosis in breast cells and tissue. Steroid 2000;65:593–8
   PubMed Web of Science ®Google Scholar
• Horwitz KB, Friedenberg GR. Growth inhibition and increase of insulin receptors in antiestrogen-resistant T47D human breast cancer cells by progestins: implication for endocrine therapies. Cancer Res 1985;45:167–73
   PubMed Web of Science ®Google Scholar
• Poulin R, Dufour JM, Labrie F. Progestin inhibition of estrogen-dependent proliferation in ZR-75-1 human breast cancer cells: antagonism by insulin. Breast Cancer Res Treat 1989;13:265–76
   PubMed Web of Science ®Google Scholar
• Musgrove EA, Lee CSL, Sutherland RL. Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor α, epidermal growth factor receptor, c-fos and c-myc genes. Mol Cell Biol 1991;11:5032–43
   PubMed Web of Science ®Google Scholar
• Groshong SD, Owen GI, Grimison B, et al. Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhitores, p21 and p27Kip1. Mol Endocrinol 1997;11:1593–607
   PubMed Web of Science ®Google Scholar
• Hissom JR, Moore MR. Progestin effects on growth in the human breast cancer cell line T47D – possible therapeutic implications. Biochem Biophys Res Commun 1987;145:706–11
   PubMed Web of Science ®Google Scholar
• Hissom JR, Bowden RT, Moore MR. Effects of progestins, estrogens and antihormones on growth and lactate dehydrogenase in the human breast cancer cell line T47D. Endocrinology 1989;125:418–23
   PubMed Web of Science ®Google Scholar
• Moore MR, Zhou J, Blankenship KA, Strobl JS, Edwards DP, Gentry RN. A sequence in the 5’ flanking region confers progestin responsiveness on the human c-myc gene. J Steriod Biochem Mol Biol 1997;62:243–52
   PubMed Web of Science ®Google Scholar
• Moore MR, Conover JL, Franks KM. Progestin effects on long-term growth, death, and bcl-xL in breast cancer cells. Biochem Biophys Res Commun 2000;277:650–4
   PubMed Web of Science ®Google Scholar
• Moore MR, Spence JB, Kiningham KK, Dillon JL. Progestin inhibition of cell death in human breast cancer cell lines. J Steriod Biochem Mol Biol 2006;98:218–27
   PubMed Web of Science ®Google Scholar
• Nardulli AM, Katzenellenbogen BS. Progesterone receptor regulation in T47D human breast cancer cells: analysis by density labeling of progesterone receptor synthesis and degradation and their modulation by progestin. Endocrinology 1988;122:1532–40
   PubMed Web of Science ®Google Scholar
• King RJ, Whitehead MI. Assessment of the potency of orally administered progestins in women. Fertil Steril 1986;46:1062–6
   PubMed Web of Science ®Google Scholar
• Svensson LO, Johnson SH, Olsson SE. Plasma concentrations of medroxyprogesterone acetate, estradiol and estrone following oral administration of Klimaxil®, Trisequence®/Provera®, and Divina®. A randomized, single-blind, triple cross-over bioavailability study in menopausal women. Maturitas 1994;18:229–38
   PubMed Web of Science ®Google Scholar
• Stanczyk FZ, Brenner PF, Mishell DR, Ortiz A, Gentzschein EKE, Goebelsmann U. A radioimmunoassay for norethindrone (NET): measurement of serum net concentrations following ingestion of NET-containing oral contraceptive steroid. Contraception 1978;18:615–33
   PubMed Web of Science ®Google Scholar
• Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371–88
   PubMed Web of Science ®Google Scholar
• Somaï S, Chaouat M, Jacob D, et al. Antiestrogens are pro-apoptotic in normal human breast epithelial cells. Int J Cancer 2003;105:607–12
   PubMed Web of Science ®Google Scholar
• Song RX, Santen RJ. Apoptotic action of estrogen. Apoptosis 2003;8:55–60
   PubMed Web of Science ®Google Scholar
• Lewis JS, Meeke K, Osipo C, et al. Intrinsic mechanism of estradiol-induced apoptosis in breast cancer cells resistant to estrogen deprivation. J Natl Cancer Inst 2005;97:1746–59
   PubMed Web of Science ®Google Scholar
• Cappelletti V, Miodini P, Fioravanti L, DiFronzo G. Effect of progestin treatment on estradiol- and growth factor-stimulated breast cancer cell lines. Anticancer Res 1995;15:2552–6
   Google Scholar
• Seeger H, Wallwiener D, Mueck AO. The effect of progesterone and synthetic progestins on serum- and estradiol-stimulated proliferation of human breast cancer cells. Hormone Metab Res 2003;35:76–80
   PubMed Web of Science ®Google Scholar
• Seeger H, Rakov V, Mueck AO. Dose-dependent changes of the ratio of apoptosis to proliferation by norethisterone and medroxyprogesterone acetate in human breast epithelial cells. Hormone Metab Res 2005;37:468–73
   PubMed Web of Science ®Google Scholar
• Krämer EA, Seeger H, Krämer B, Wallwiener D, Mueck AO. The effects of progesterone, medroxyprogesterone acetate, and norethisterone on growth factor- and estradol-treated human cancerous and noncancerous breast cells. Menopause 2005;12:468–74
   PubMed Web of Science ®Google Scholar
• Schoonen WGEJ, Joosten JWH, Kloosterboer B, Wallwiener HJ. Effects of two classes of progestogens, pregnane and 19-nortestosterone derivatives, on cell growth of human breast tumor cells. 1. MCF-7 cell lines. J Steroid Biochem Mol Biol 1995;55:423–37
   PubMed Web of Science ®Google Scholar
• Franke HR, Vermes I. Differential effects of progestogens on breast cancer cell lines. Maturitas 2003;46(Suppl 1):S55–8
   PubMedGoogle Scholar
• Mueck AO, Seeger H, Wallwiener D. Comparison of the proliferative effects of estradiol and conjugated equine estrogens on human breast cancer cells and impact of continuous combined progestogen addition. Climacteric 2003;6:221–7
   PubMed Web of Science ®Google Scholar
• Woodward TL, Xie JW, Haslam SZ. The role of mammary stroma in modulating the proliferative response to ovarian hormone in the normal mammary gland. J Mammary Gland Biol Neoplasia 1998;3:117–31
   PubMed Web of Science ®Google Scholar
• Noel A, Foidart JM. The role of stroma in breast carcinoma growth in vivo. J Mammary Gland Biol Neoplasia 1998;3:215–25
   PubMed Web of Science ®Google Scholar